The company's next-generation sequencing-based test detects more than 400 recurrent alterations that can identify 96 percent of bladder cancers.
Data from an early-phase trial has spurred the firm to validate its blood-based residual disease assay, Radar, in neoadjuvant bladder cancer.
KDx Diagnostics Inks US Distribution Deal for Bladder Cancer Test
URO17 uses the oncoprotein keratin 17 as a biomarker to detect new and recurrent bladder cancer and is available as a laboratory-developed test.
Diagnostics Developer Early is Good Raises $4M in Seed Funding
The company will use the funds to complete clinical trials for its first product, BCDx, a laboratory-developed test for early bladder cancer detection.
Nucleix Expands EU Label Indication for Bladder Cancer Urine Test
The test measures DNA methylation patterns in urine that are associated with urothelial cancer and was first launched for monitoring tumor recurrence.